- Pharmanutra

08 November 2023

MODEL DISCLOSURE FOR TRANSACTIONS IN THE ISSUER’S SECURITIES

06 November 2023

BOD APPROVES INTERIM MANAGEMENT REPORT AS AT 30/09/2023

10 October 2023

PHARMANUTRA S.P.A.: INITIATION OF SHARE BUY-BACK PROGRAM

03 October 2023

PHARMANUTRA S.P.A.: FIRST SALES ON THE US MARKET

19 September 2023

PHARMANUTRA S.P.A.: HALF-YEAR FINANCIAL REPORT AS OF 30 JUNE 2023

12 September 2023

POLICY FOR THE MANAGEMENT OF THE DIALOGUE WITH ALL SHAREHOLDERS OF PHARMANUTRA S.P.A.

11 September 2023

PHARMANUTRA S.P.A.: THE BOD APPROVED THE FIRST HALF FINANCIAL REPORT AS AT 30 JUNE 2023

30 August 2023

PHARMANUTRA S.P.A.: LIPOCET (CETILAR®) GETS THE GREEN LIGHT TO BE CLASSIFIED AS A ‘NOVEL FOOD’ ALSO IN THE UK

03 August 2023

PHARMANUTRA S.P.A.: CETILAR® WITH MARCELL JACOBS HEADING FOR PARIS 2024

17 July 2023

PHARMANUTRA S.P.A.: THE BOARD OF DIRECTORS APPROVES THE 2022 SUSTAINABILITY REPORT AND APPOINTS THE SUSTAINABILITY GOVERNANCE

11 July 2023

PHARMANUTRA S.P.A.: CETILAR® IS RECONFIRMED AS MAIN SPONSOR OF THE PISA SPORTING CLUB FOR 2023-2024

26 May 2023

PHARMANUTRA S.P.A.: CETILAR® SIDE BY SIDE WITH FERNANDO ALONSO

1 2 … 17 >